AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Set up an RSS feed
Create a link to this page
Copy and paste this link tag into your Web page or blog:
BioWorld Week back issues
|
|
Protein sciences wins $35m HHS pact, despite creditors.
June 29, 2009... Privately held Protein Sciences Corp. Inc. won a $35 million Health and Human Services contract, which could be extended to $147 million over five years, to support the Meriden, Conn.-based firm's recombinant baculovirus influenza vaccine technology.
However, Protein Sciences' creditors,...
Immunoproteasome blocker as weapon against arthritis.(News From The Lab)
June 29, 2009... Inhibiting the proteasome has proven to be a winning strategy against hematological cancers: Velcade (bortezomib), from Takeda subsidiary Millennium Inc., works by inhibiting the proteasome, and several other proteasome inhibitors are in clinical trials. In the June 14, 2009, issue of Nature...
Bill for SBIR, STTR grants in Senate.(Monday, June 22)
June 29, 2009... Legislation introduced earlier this month by Sens. Mary Landrieu (D-La) and Olympia Snowe (R-Maine) to reauthorize the Small Business Innovation Research and the Small Business Technology Transfer programs was quickly passed recently by the Senate Committee on Small Business and...
NeurogesX's Qutenza deal shifts focus to U.S. filing.(Tuesday, June 23)
June 29, 2009... With the PDUFA date for its capsaicin pain patch Qutenza (capsaicin 179 mg) rapidly approaching, NeurogesX Inc. gained a nice chunk of cash and squared . away European rights to the product in a potential (:105 million (US$145.5 million) deal with Astellas Pharma Inc. San Mateo, Calif.-based...
Oncothyreon's cancer vaccine starts 2nd Phase III.(Tuesday, June 23)
June 29, 2009... With a Phase III trial in non-small-cell lung cancer well under way, Merck KGaA, of Darmstadt, Germany, started a second Phase III trial, this time in breast cancer, with Oncothyreon Inc.'s cancer vaccine Stimuvax. The news "was not unexpected to investors familiar with the story" and with...